EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte Studie

Cefepime–Taniborbactam in Complicated Urinary Tract Infection

Florian M Wagenlehner, Leanne B Gasink, Paul C McGovern iD, Greg Moeck, Patrick McLeroth, MaryBeth Dorr, Aaron Dane, Tim Henkel, CERTAIN-1 Study Team

New England Journal of Medicine · 15.02.2024 · 390 (7) · 611-622

DOI: 10.1056/nejmoa2304748 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 15.02.2024. Verfasst von Florian M Wagenlehner und 8 weiteren Autor:innen. Beteiligte Einrichtung: From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M.,…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Borinic Acids, Carboxylic Acids, Cefepime. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Biomedical Advanced Research and Development Authority, Global Antibiotic Research and Development Partnership, Everest Medicines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBorinic AcidsCarboxylic AcidsCefepimeMeropenemUrinary Tract InfectionsAdultAgedHumansMiddle AgedAdministration, IntravenousBacteremiabeta-LactamasesDrug Therapy, CombinationHospitalizationMicrobial Sensitivity TestsPyelonephritisDrug Resistance, Bacterial

Substanzen

Anti-Bacterial Agentsbeta-LactamasesBorinic AcidsCarboxylic AcidsCefepimeMeropenemtaniborbactam

Autor:innen und Institutionen

  • From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) - both in Pennsylvania; Fortrea, Burlington, NC (P.M.); a…

ORCID-Profile: Paul C McGovern

Förderung

  • Biomedical Advanced Research and Development Authority
  • Global Antibiotic Research and Development Partnership
  • Everest Medicines

Zitieren

APA

Wagenlehner, F. M., Gasink, L. B., McGovern, P. C., Moeck, G., McLeroth, P., Dorr, M., Dane, A., Henkel, T., & CERTAIN-1 Study Team (2024). Cefepime–Taniborbactam in Complicated Urinary Tract Infection. New England Journal of Medicine, 390(7), 611-622. https://doi.org/10.1056/nejmoa2304748

Vancouver

Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. Cefepime–Taniborbactam in Complicated Urinary Tract Infection. New England Journal of Medicine. 2024;390(7):611-622. doi:10.1056/nejmoa2304748

BibTeX
@article{Wagenlehner2024,
  author = {Wagenlehner, Florian M and Gasink, Leanne B and McGovern, Paul C and Moeck, Greg and McLeroth, Patrick and Dorr, MaryBeth and Dane, Aaron and Henkel, Tim and CERTAIN-1 Study Team, CERTAIN-1 Study Team},
  title = {Cefepime–Taniborbactam in Complicated Urinary Tract Infection},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {7},
  pages = {611--622},
  doi = {10.1056/nejmoa2304748}
}
Kostenlos starten →